The effect of misoprostol on myomectomy

Comparison of outcomes and complications of vaginal misoprostol Preoperative administration of oxytousin infusion during surgery to reduce bleeding during abdominal myomectomy

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

IRCT

Registry ID

IRCT2014050210901N6

Enrollment

105

Registered

2014-05-09

Start date

2013-11-29

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Uterine myoma. Leiomyoma of uterus, unspecified

Interventions

Intervention 1: infusion oxytocin 30 unit into 1000 ml normal saline speed of 120 ml/hour before starting anesthesia to Removing the compelete uterine from pelvic. Intervention 2: A single dose of 400

Prevention

infusion oxytocin 30 unit into 1000 ml normal saline speed of 120 ml/hour before starting anesthesia to Removing the compelete uterine from pelvic

A single dose of 400 mcg of misoprostol vaginally one hour before surgery

non adminestration drug before and during surgery

Eligibility

Sex/Gender

Female

Inclusion criteria

Inclusion criteria: Inclusion criteria: the desire to participate in the study Exclusion Criteria: allergy to misoprostol or oxytocin; hormone therapy before surgery or gonadotropin releasing drugs such as oral contraceptive pills; active liver disorders - kidney disease - heart - lung ; candidates hysteroscopic myomectomy; hypertension ;coagulopathy

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Bleeding. Timepoint: Day intervention. Method of measurement: The blood volume (amount of suction blood and blood absorbed in sponges to longGas 50cc and gas 5cc ).	—

Secondary

Measure	Time frame
Duration of hospital stay. Timepoint: Since the intervention to patient discharge from the hospital. Method of measurement: documentation in the file.;Duration of surgery. Timepoint: Begin operation until the completion of surgery. Method of measurement: documentation in the file.;Hemoglubin 6 hours after Surgery. Timepoint: 6 hours after intervention. Method of measurement: Testing the file.;Hemoglubin 24 hour after surgery. Timepoint: 24 hours after intervention. Method of measurement: Testing the file.;Blood transfusion. Timepoint: Since the intervention to patient discharge from the hospital. Method of measurement: documentation in the file.	—

Measure

Time frame

Duration of hospital stay. Timepoint: Since the intervention to patient discharge from the hospital. Method of measurement: documentation in the file.;Duration of surgery. Timepoint: Begin operation until the completion of surgery. Method of measurement: documentation in the file.;Hemoglubin 6 hours after Surgery. Timepoint: 6 hours after intervention. Method of measurement: Testing the file.;Hemoglubin 24 hour after surgery. Timepoint: 24 hours after intervention. Method of measurement: Testing the file.;Blood transfusion. Timepoint: Since the intervention to patient discharge from the hospital. Method of measurement: documentation in the file.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactSakineh Alizadeh doctor

Resident Obstetric

s.alizadeh80@yahoo.com+98 41 1553 9163

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026